66 related articles for article (PubMed ID: 24132142)
1. A heterodimeric Fc-based bispecific antibody simultaneously targeting VEGFR-2 and Met exhibits potent antitumor activity.
Choi HJ; Kim YJ; Lee S; Kim YS
Mol Cancer Ther; 2013 Dec; 12(12):2748-59. PubMed ID: 24132142
[TBL] [Abstract][Full Text] [Related]
2. Suppression of c-Met-Overexpressing Tumors by a Novel c-Met/CD3 Bispecific Antibody.
Huang L; Xie K; Li H; Wang R; Xu X; Chen K; Gu H; Fang J
Drug Des Devel Ther; 2020; 14():3201-3214. PubMed ID: 32982167
[TBL] [Abstract][Full Text] [Related]
3. Development of a c-MET x CD137 bispecific antibody for targeted immune agonism in cancer immunotherapy.
Zhang H; Wang Q; Yalavarthi S; Pekar L; Shamnoski S; Hu L; Helming L; Zielonka S; Xu C
Cancer Treat Res Commun; 2024; 39():100805. PubMed ID: 38492435
[TBL] [Abstract][Full Text] [Related]
4. A Novel Dual-Fc Bispecific Antibody with Enhanced Fc Effector Function.
Zhou F; Ben Y; Jiang H; Tan S; Mu G; Zha Z; Dong S; Huang S; Zhou Y; Jin Y; Chiu ML
Biochemistry; 2024 Apr; 63(8):958-968. PubMed ID: 38426700
[TBL] [Abstract][Full Text] [Related]
5. Bispecific Antibodies for IFN-β Delivery to ErbB2
Rybchenko VS; Panina AA; Aliev TK; Solopova ON; Balabashin DS; Novoseletsky VN; Dolgikh DA; Sveshnikov PG; Kirpichnikov MP
Biomolecules; 2021 Dec; 11(12):. PubMed ID: 34944558
[TBL] [Abstract][Full Text] [Related]
6. Pretargeted delivery of PEG-coated drug carriers to breast tumors using multivalent, bispecific antibody against polyethylene glycol and HER2.
Parker CL; McSweeney MD; Lucas AT; Jacobs TM; Wadsworth D; Zamboni WC; Lai SK
Nanomedicine; 2019 Oct; 21():102076. PubMed ID: 31394261
[TBL] [Abstract][Full Text] [Related]
7. A novel bivalent anti-c-MET/PD-1 bispecific antibody exhibits potent cytotoxicity against c-MET/PD-L1-positive colorectal cancer.
Sun Z; Gu C; Wang X; Shang A; Quan W; Wu J; Ji P; Yao Y; Liu W; Li D
Invest New Drugs; 2023 Oct; 41(5):737-750. PubMed ID: 37646958
[TBL] [Abstract][Full Text] [Related]
8. Structural and Functional Characterization of a Hole-Hole Homodimer Variant in a "Knob-Into-Hole" Bispecific Antibody.
Zhang HM; Li C; Lei M; Lundin V; Lee HY; Ninonuevo M; Lin K; Han G; Sandoval W; Lei D; Ren G; Zhang J; Liu H
Anal Chem; 2017 Dec; 89(24):13494-13501. PubMed ID: 29129068
[TBL] [Abstract][Full Text] [Related]
9. Development of a Bispecific IgG1 Antibody Targeting BCMA and PDL1.
Cattaneo I; Choblet S; Valgardsdottir R; Roth M; Massafra A; Beeg M; Gobbi M; Duonor-Cerutti M; Golay J
Antibodies (Basel); 2024 Feb; 13(1):. PubMed ID: 38390876
[TBL] [Abstract][Full Text] [Related]
10. CaptureSelect FcXP affinity medium exhibits strong aggregate separation capability.
Dong W; Zhang D; Li Y
Protein Expr Purif; 2024 Aug; 220():106503. PubMed ID: 38759705
[TBL] [Abstract][Full Text] [Related]
11. Single-Molecule 3D Images of "Hole-Hole" IgG1 Homodimers by Individual-Particle Electron Tomography.
Lei D; Liu J; Liu H; Cleveland TE; Marino JP; Lei M; Ren G
Sci Rep; 2019 Jun; 9(1):8864. PubMed ID: 31221961
[TBL] [Abstract][Full Text] [Related]
12. Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions.
Abdeldaim DT; Schindowski K
Pharmaceutics; 2023 Sep; 15(10):. PubMed ID: 37896162
[TBL] [Abstract][Full Text] [Related]
13. Crystal structures of immunoglobulin Fc heterodimers reveal the molecular basis for heterodimer formation.
Choi HJ; Seok SH; Kim YJ; Seo MD; Kim YS
Mol Immunol; 2015 Jun; 65(2):377-83. PubMed ID: 25743157
[TBL] [Abstract][Full Text] [Related]
14. Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins.
Ha JH; Kim JE; Kim YS
Front Immunol; 2016; 7():394. PubMed ID: 27766096
[TBL] [Abstract][Full Text] [Related]
15. An efficient route to human bispecific IgG.
Merchant AM; Zhu Z; Yuan JQ; Goddard A; Adams CW; Presta LG; Carter P
Nat Biotechnol; 1998 Jul; 16(7):677-81. PubMed ID: 9661204
[TBL] [Abstract][Full Text] [Related]
16. 'Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerization.
Ridgway JB; Presta LG; Carter P
Protein Eng; 1996 Jul; 9(7):617-21. PubMed ID: 8844834
[TBL] [Abstract][Full Text] [Related]
17. Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2-CH3 hydrophobic interaction.
Elliott JM; Ultsch M; Lee J; Tong R; Takeda K; Spiess C; Eigenbrot C; Scheer JM
J Mol Biol; 2014 May; 426(9):1947-57. PubMed ID: 24576605
[TBL] [Abstract][Full Text] [Related]
18. LY2875358, a neutralizing and internalizing anti-MET bivalent antibody, inhibits HGF-dependent and HGF-independent MET activation and tumor growth.
Liu L; Zeng W; Wortinger MA; Yan SB; Cornwell P; Peek VL; Stephens JR; Tetreault JW; Xia J; Manro JR; Credille KM; Ballard DW; Brown-Augsburger P; Wacheck V; Chow CK; Huang L; Wang Y; Denning I; Davies J; Tang Y; Vaillancourt P; Lu J
Clin Cancer Res; 2014 Dec; 20(23):6059-70. PubMed ID: 25231402
[TBL] [Abstract][Full Text] [Related]
19. Preferential species-restricted heavy/light chain pairing in rat/mouse quadromas. Implications for a single-step purification of bispecific antibodies.
Lindhofer H; Mocikat R; Steipe B; Thierfelder S
J Immunol; 1995 Jul; 155(1):219-25. PubMed ID: 7602098
[TBL] [Abstract][Full Text] [Related]
20. Design and engineering of bispecific antibodies: insights and practical considerations.
Madsen AV; Pedersen LE; Kristensen P; Goletz S
Front Bioeng Biotechnol; 2024; 12():1352014. PubMed ID: 38333084
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
